drugset / Trial / NCT00828308

Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer

NCT00828308

NaSingle-groupOpen-labelTreatment

Summary

Ixabepilone, 16 mg/m2 or 20mg/m2, weekly x 3, in 4 week cycles, x 4 cycles. Prostatectomy 2-8 weeks after completion(standard of care and not a part of study)

Timeline

Start
2009-02
Primary completion
2011-03
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ixabepilone Small molecule 16 mg/m2
Subject Ixabepilone Small molecule 20 mg/m2

Indications